Result. We have included a total of 11635698 participants who experienced nephrolithiasis 44 from a total of six clinical studies with nephrolithiasis rates of 1,27% in the SGLT2i group (n 45 = 739197), compared to 1,56% in the control arm (n = 10896501). SGLT-2 inhibitor therapy 46 has been associated with a lower risk for nephrolithiasis compared … Leggi tutto
Type 2 diabetes (T2D) is associated with an increased risk of kidney stones. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) might lower the risk of nephrolithiasis by altering urine composition. However, no studies have investigated the association between SGLT2i use and nephrolithiasis risk in patients receiving routine care in the US. After 1:1 propensity score matching, a … Leggi tutto
Shock wave lithotripsy (SWL) has proven to be a highly effective treatment for the removal of kidney stones. Shock waves (SWs) can be used to break most stone types, and because lithotripsy is the only noninvasive treatment for urinary stones, SWL is particularly attractive. On the downside SWL can cause vascular trauma to the kidney … Leggi tutto
Pharmacological therapy may be useful in the treatment of moderate to severe hypercalcemia in patients with infantile hypercalcemia-1 (HCINF1) due to pathogenic variants in the cytochrome P450 24 subfamily A member 1 (CYP24A1). Rifampin is an antituberculosis drug that is a potent inducer of cytochrome P450 3 subfamily A member 4, which is involved in … Leggi tutto
Nephrolithiasis remains a formidable health problem in the United States and worldwide. A very important butunderaddressed area in nephrolithiasis is the accompanying bone disease. Epidemiologic studies have shown that osteoporotic fractures occur more frequently in patients with nephrolithiasis than in the general population. Decreased bone mineral density and defects in bone remodeling are commonly encountered … Leggi tutto
Context: Diabetes mellitus is a risk factor for nephrolithiasis. A recent observational study found that in patients with type 2 diabetes (T2D), SGLT2 inhibitor use was associated with a 49% lower risk of nephrolithiasis compared with GLP-1 receptor agonists. Objective: We examined the association between nephrolithiasis and the SGLT2 inhibitor empagliflozin, using existing data from … Leggi tutto
… Results We identified 24,290 and 19,576 eligible users of SGLT2Is and GLP1 RAs, respectively. After matching, 12,325 patient pairs remained. The median age was 61 years and median follow-up was 2.0 years. The nephrolithiasis rate was 2.0 per 1000 person-years in SGLT2I initiators compared with 4.0 per 1000 person-years in GLP1 RA initiators, with a rate … Leggi tutto
La storia naturale della calcolosi urinaria è quella di una patologia che tende a recidivare e che può associarsi ad aumentato rischio di malattia renale cronica, ossea e cardiovascolare. Per questo una ampia valutazione clinico-metabolica del paziente è di grande importanza sin dalla prima presentazione della calcolosi, allo scopo di impostare un appropriato trattamento preventivo. … Leggi tutto
This publication is printed and distributed for educational purposes by MISSION PHARMACAL COMPANY San Antonio, TX 78230-1355 Acknowledgment is made to the following people for expert guidance on the development of this booklet 0 0 0 0